Models of hepatocellular carcinoma and biomarker strategy

Cancers

Volumn 2, Issue 3, 2010, Pages 1441-1452

  Bagi, Cedo M ^a   Andresen, Catharine J ^a  

^a PFIZER INC   (United States)

Author keywords

Cell cocktail; CEUS; HCC; Histology; Liver vasculature; MRI; Orthotopic models; PET

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DOXORUBICIN; SUNITINIB;

BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; ECHOGRAPHY; EXPERIMENTAL ANIMAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CIRCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR XENOGRAFT;

EID: 79952268001     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2031441     Document Type: Review

References (51)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globcon 2000. Int. J. Cancer 2001, 94, 153-156.
2. El Serag, H.B.; Mason, A.C. Rising incidence of hepatocellular carcinoma in the United States. N. Eng. J. Med. 1999, 340, 745-750.
3. Dalton, W.S; Friend, S.H. Cancer biomarkers-An invitation to the table. Science 2006, 312, 1165-1168.
4. Nerenstone, S.R.; Ihde, D.C.; Friedeman, M.A. Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat. Rev. 1988, 15, 1-31.
5. Lai, C.-L.; Wu, P.-C.; Chan, G.C.B.; Lok, A.S.F.; Lin, H.-J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 1988, 62, 479-483.
6. Strumberg, D.; Richly, H.; Hilger, R.A.; Schleucher, N.; Kofee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C.G., et al. Clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 2005, 23, 965-972.
7. Llovet, J.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Raoul, J.; Zeuzem, S.; Paulin-Costello, M.; Moscovici, M.; Voliotis, D.; Bruix, J. For the SHARP Investigators Study Group. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Results of phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol. 2007, 25, Abstr. LBA1.
8. Abou Alfa, G.K.; Johnson, P.; Knox, J.; Lacava, J.; Leung, T.; Mori, A.; Leberre, M.A.; Voliotis, D.; Saltz, L. Preliminary results from a phase II, rendomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur. J. Cancer 2007, 5, 259.
9. Zhu, A.X.; Sahani, D.V.; de Tomaso, E.; Duda, D.; Sindhwani, V.; Yoon, S.S.; Blaszkowsky, L.S.; Clark, J.W.; Ryan, D.P.; Jain, R.K. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2007, 25, Abstr. 4637.
10. Faivre, S.J.; Raymond, E.; Douillard, J.; Boucher, E.; Lim, H.Y.; Kim, J.S.; Lanzalone, S.; Lechuga, M.J.; Sherman, L.; Cheng, A. Assessment of safety and drug-induced tumor necrosis with sunitanib in patients with unresectable hepatocellular carcinoma (HCC). J. Clin. Oncol. 2007, 25, Abstr. 3546.
11. Yang, R.; Rescoria, F.J.; Reilly, C.R.; Faught, P.R.; Sanghvi, N.T.; Lumeng, L.; Franklin, T.D; Grosfeld, J.L. A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation. J. Surg. Res. 1992, 52, 193-198.
12. Bagi, C.M. Challenges in Developing Preclinical Models of Hepatocellular Carcinoma. 7th Annual Cancer Drugs. In Research and Development Conference, San Diego, CA, USA, 2010; pp. 163-170.
13. Sun, F.X.; Tang, Z.Y.; Liu, K.D.; Ye, S.L.; Xue, Q.; Gao, D.M.; Ma, Z.C. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int. J. Cancer 1996, 66, 239-243.
14. Hoffman, R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs 1999, 17, 343-359.
15. Gutmann, D.H.; Hunter-Schaedle, K.; Shannon, K.M. Harnessing preclinical mouse models to inform human cancer trials. J. Clin. Invest. 2006, 116, 847-852.
16. Kramer, M.G.; Hernandez-Alcoceba, R.; Qian, C.; Prieto, J. Evaluation of hepatocellular carcinoma models for preclinical research. Drug Discovery Today: Disease models. Drug Disc. Today 2005, 2, 41-49.
17. Daniel, V.C.; Marchionni, L.; Hierman, J.S.; Rhodes, J.T.; Devereux, W.L.; Rudin, C.M.; Young, R.; Parmigiani, G.; Dorsch, M.; Peacock, C.D.; Watkins, D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009, 69, 3364-3373.
18. Marx, J. Medicine. Building better mouse models for studying cancer. Science 2003, 299, 1972-1975.
19. Simonetti, R.G.; Cottone, M.; Craxi, A.; Pagliaro, L.; Rapicetta, M.; Chionne, P.; Costantino, A. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. Lancet 1989, 2, 1338.
20. Patt, Y.Z.; Charnsangavej, B.; Yoffe, R.; Smith, R.; Lawrence, D.; Chuang, V.; Carrasco, H.; Roh, M.; Chase, J.; Fisher, H. Hepatic arterial infusion of floxouridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival. J. Clin. Oncol. 1994, 12,1204-1211.
21. Buendia, M.A. Hepatitis, B. Viruses and hepatocellular carcinoma. Adv. Cancer Res. 1992, 59, 167-226.
22. Okubo, H.; Takei, Y.; Serizawa, N.; Enomoto, N.; Ikejima, K.; Sato, N. Orthotopic hepatocellular carcinoma model with a controlled and reproducible tumorogenicity. Hepatology 2007, 22, 423-428.
23. Killion, J.J.; Radinsky, R.; Fidler, I.J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998, 17, 279-284.
24. Frijhoff, A.F.; Conti, C.J.; Sanderowicz, A.M. Advances in molecular carcinogenesis: Current and future use of mouse models to screen and validate molecularly targeted anticancer drugs. Mol. Carcinog. 2004, 39, 183-194.
25. Barajas, M.; Mazzolini, G.; Genove, G.; Bilbao, R.; Narvaiza, I.; Schmitz, V.; Sangro, B.; Melero, I.; Qian, C.; Prieto, J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001, 33, 52-61.
26. Wilmanns, C.; Fan, D.; O'Brian, C.A.; Bucana, C.D.; Fidler, I.J. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int. J. Cancer 1992, 52, 98-104.
27. Labonte, P.; Kadhim, S.; Bowlin, T.; Mounir, S. Inhibitionof tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model. Hepatol. Res. 2000, 18, 72-85.
28. Davis, H.C.; Morse, I.S. Segmental liver revascularization. Arch. Surg. 1957, 74, 525-527.
29. McCuskey, R.S. The hepatic microvascular system. In The Liver: Biology Pathology; Arias, I.M., Boyer, J.L., Fausto, N., Jacoby, B.W., Schachter, D.A., Shafritz, D.A., Eds.; Raven Press: New York, NY, USA, 1994; pp. 1089-1106.
30. Rubaltelly, L.; Maschio, A.; Candiani, F.; Miotto, D. The role of vascularization in the formation of echographic patterns of hepatic metastases: microangiographic and echographic study. Br. J. Radiol. 1980, 53, 1166-1168.
31. Archer, S.G.; Gray, B.N. Vascularization of small liver metastases. Br. J. Surg. 1989, 76, 545-548.
32. Nakashima, Y.; Nakashima, O.; Hsia, C.C.; Kojiro, M.; Tabor, E. Vascularization of small hepatocellular carcinomas: correlation with differentiation. Liver 1999, 19, 12-18.
33. Matsui, O.; Kadoya, M.; Kameyama, T.; Yoshikawa, J.; Takashima, T.; Nakanuma, Y.; Unoura, M.; Kobayashi, K.; Izumi, R.; Ida, M. Benign and malignant nodulus in cirrhotic liver: distinction based on blood supply. Radiology 1991, 178, 493-497.
34. Ackerman, N.B. The blood supply of experimental liver metastasis: IV. Changes in vascularity with increasing tumor growth. Surgery 1974, 75, 589-596.
35. Ishikawa, T.; Imai, M.; Kamimura, H.; Tsuchiya, A.; Togashi, T.; Watanabe, K.; Seki, K.-I.; Ohta, H.; Yoshida, T.; Kemimura, T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tagafur/uracil: A pilot study. World J. Gastroenterol. 2007, 13, 5465-5470.
36. Jarnagin, W.R.; Schwartz, L.H.; Gultekin, D.H.; Gönen, M.; Haviland, D.; Shia, J.; D'Angelica, M.; Fong, Y.; DeMatteo, R.; Tse, A.; Blumgart, L.H.; Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of phase II clinical trial and assessment of DCE-MRI as biomarker of survival. Annal. Oncol. 2009, 20, 1589-1595.
37. Fracanzani, A.L.; Burdick, L.; Borzio, M.; Roncalli, M.; Bonelli, N.; Borzio, F.; Maraschi, A.; Fiorelli, G.; Fargion, S. Contrast enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 2001, 34, 1109-1112.
38. Delbeke, D.; Martin, W.H.; Sandler, M.P.; Chapman, W.C.; Wright, J.K.; Pinson, C.W. Evaluation of benign vs. Malignant hepatic lesions with positron emission tomography. Arch. Surg. 1998, 133, 510-515.
39. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J. Nucl. Med. 2003, 44, 213-221.
40. Olivia, M.R.; Saini, S. Liver cancer imaging: role of CT, MRI, US and PET. Cancer Imaging 2004, 4, S42-S46.
41. Saini, S.; Nelson, R.C. Technique for MR imaging of the liver. Radiology 1995, 197, 575-577.
42. Weinmann, H.J.; Ebert, W.; Misselwitz, B.; Schmitt-Willich, H. Tissue-specific MR contrast agents. Eur. J. Radiol. 2003, 46, 33-44.
43. Soling, A.; Rainov, N.G. Bioluminescence imaging in vivo - application to cancer research. Expert. Opin. Biol. Ther. 2003, 3, 1163-1172.
44. Sarraf-Yazdi, S.; Mi, J.; Dewhirst, M.W.; Clary, B.M. Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice. J. Surg. Res. 2004, 120, 249-255.
45. Ives, A.A.; Pathan, A.A.; Navarrete, C.V.; Williams, R.; Bertoletti, A.; Behboudi, S. Analysis of CD4+ T-cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin. Cancer Res. 2005, 11, 6686-6694.
46. McIntire, K.R.; Vogel, C.L.; Primack, A.; Waldmann, T.A.; Kyalwazi, S.K. Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer 2006, 37, 677-683.
47. Bagi, C.M.; Christensen, J.; Cohen, D.P.; Roberts, G.W.; Wilkie, D.; Swanson, T.; Tuthill, T. Andresen, J.C. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol. Ther. 2009, 8, 1-10.
48. Boukaz, A.; de Jong, N. WFUMB safety symposium on echo-contrast agents: nature and types of ultrasound contrast agents. Ultrasound Med. Biol. 2007, 33, 187-196.
49. Bekeredjian, R.; Kroll, R.D.; Fein, E.; Tinkov, S.; Coester, C.; Winter, G.; Katus, H.A.; Kulaksiz, H. Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med. Biol. 2007, 33, 1592-1598.
50. Lassau, N.; Chebil, M.; Chami, L.; Roche, A. A new functional imaging technique for the early functional evaluation of antiangiogenic treatment: dynamic contrast-enhanced ultrasonography (DCE-US). Targ. Oncol. 2008, 3, 111-117.
51. Kang, J.; Wu, X.; Wang, Z.; Ran, H.; Xu, C.; Wu, J.; Wang, Z.; Zhang, Y. Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. J. Ultrasound Med. 2010, 29, 61-70.